세계의 체외 독성 시험 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2023-2030년)

The global demand for In Vitro Toxicity Testing Market is presumed to reach the market size of nearly USD 34.34 MN by 2030 from USD 13.46 MN in 2022 with a CAGR of 12.42% under the study period 2023 - 2030.

In vitro toxicity testing is a research-based evaluation of the effects of toxic chemicals on cultured bacteria or mammalian cells. In vitro studies (i.e., in glass) are performed against microorganisms, cells, or biological molecules outside of normal biological conditions. When testing a drug in vitro, the concentration of the drug is limited to a known volume. This is critical because all drug behaviour assessments are essentially demonstrated at defined proportions. This is primarily done to assess the safety of drug development and chemical strength. The goal of toxicity testing is to develop data that can adequately protect public health from the adverse effects of exposure to environmental factors.

MARKET DYNAMICS:

The growth in technological advancement to evaluate drug safety, the upsurge in consumer goods safety, the increase in ranking and screening of potential drugs, and the rise in the number of in-vitro tests conducted are key industry drivers for in-vitro toxicology testing. In addition, increased investment in research and development and opposition to animal testing prompted in-vitro toxicology testing. However, the government's stringent regulations and a lack of professionals are significant barriers to in-vitro testing.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of in vitro toxicity testing. The growth and trends of in vitro toxicity testing industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the in vitro toxicity testing market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product & Service

• Covid Impact
• Consumables
• Assays (Bacterial Toxicity Assays, Enzyme Toxicity Assays, Cell-Based Elisa & Western Blots, Receptor-Binding Assays, Tissue Culture Assays, Other Assays)
• Equipment
• Software
• Services

By Method

• Cellular Assays
• Biochemical Assays
• In Silico Models
• Ex Vivo Models

By Toxicity Endpoint & Test

• ADME
• Skin Irritation, Corrosion, & Sensitization
• Genotoxicity Testing
• Cytotoxicity Testing
• Ocular Toxicity
• Organ Toxicity
• Phototoxicity Testing
• Dermal Toxicity
• Other Toxicity Endpoints & Tests

By Industry

• Covid Impact
• Pharmaceuticals & Biopharmaceuticals
• Cosmetic & Household Products
• Food
• Chemicals

By Technology

• Cell Culture Technologies
• High-Throughput Technologies
• Toxicogenomics

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the In Vitro Toxicity Testing market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the in vitro toxicity testing market include Thermo Fisher Scientific Inc. (US), Covance (US), Bio-Rad Laboratories, Inc. (US), GE Healthcare (US), Eurofins Scientific SE (Luxembourg), Merck KGaA (Germany), Charles River Laboratories International, Inc. (US), Catalent, Inc. (US), Cyprotex (UK), SGS S.A. (Switzerland), QIAGEN N.V. (Germany), Promega Corporation (US), Gentronix Limited (UK), BioIVT (US), and MB Research Laboratories (US). This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

• 1.1. Report Description
  • 1.1.1. Objective
  • 1.1.2. Target Audience
  • 1.1.3. Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1. Market Research Process
  • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3 . IN VITRO TOXICITY TESTING - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Product & Service
  • 3.7.2 Market Attractiveness Analysis By Method
  • 3.7.3 Market Attractiveness Analysis By Toxicity Endpoint & Test
  • 3.7.4 Market Attractiveness Analysis By Industry
  • 3.7.5 Market Attractiveness Analysis By Technology
  • 3.7.6 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1. List of Raw Materials
  • 4.2.2. Raw Material Manufactures List
  • 4.2.3. Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1. Direct Marketing
  • 4.4.2. Indirect Marketing
  • 4.4.3. Marketing Channel Development Trend

5. IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL IN VITRO TOXICITY TESTING MARKET ANALYSIS BY PRODUCT & SERVICE

• 6.1 Overview by Product & Service
• 6.2 Historical and Forecast Data
• 6.3 Analysis by Product & Service
• 6.4 Covid Impact Historic and Forecast Sales by Regions
• 6.5 Consumables Historic and Forecast Sales by Regions
• 6.6 Assays (Bacterial Toxicity Assays, Enzyme Toxicity Assays, Cell-based Elisa & Western Blots, Receptor-binding Assays, Tissue Culture Assays, Other Assays) Historic and Forecast Sales by Regions
• 6.7 Equipment Historic and Forecast Sales by Regions
• 6.8 Software Historic and Forecast Sales by Regions
• 6.9 Services Historic and Forecast Sales by Regions

7 . GLOBAL IN VITRO TOXICITY TESTING MARKET ANALYSIS BY METHOD

• 7.1 Overview by Method
• 7.2 Historical and Forecast Data
• 7.3 Analysis by Method
• 7.4 Cellular Assays Historic and Forecast Sales by Regions
• 7.5 Biochemical Assays Historic and Forecast Sales by Regions
• 7.6 In Silico Models Historic and Forecast Sales by Regions
• 7.7 Ex Vivo Models Historic and Forecast Sales by Regions

8 . GLOBAL IN VITRO TOXICITY TESTING MARKET ANALYSIS BY TOXICITY ENDPOINT & TEST

• 8.1 Overview by Toxicity Endpoint & Test
• 8.2 Historical and Forecast Data
• 8.3 Analysis by Toxicity Endpoint & Test
• 8.4 ADME Historic and Forecast Sales by Regions
• 8.5 Skin Irritation, Corrosion, & Sensitization Historic and Forecast Sales by Regions
• 8.6 Genotoxicity Testing Historic and Forecast Sales by Regions
• 8.7 Cytotoxicity Testing Historic and Forecast Sales by Regions
• 8.8 Ocular Toxicity Historic and Forecast Sales by Regions
• 8.9 Organ Toxicity Historic and Forecast Sales by Regions
• 8.10. Phototoxicity Testing Historic and Forecast Sales by Regions
• 8.11 Dermal Toxicity Historic and Forecast Sales by Regions
• 8.12 Other Toxicity Endpoints & Tests Historic and Forecast Sales by Regions

9 . GLOBAL IN VITRO TOXICITY TESTING MARKET ANALYSIS BY INDUSTRY

• 9.1 Overview by Industry
• 9.2 Historical and Forecast Data
• 9.3 Analysis by Industry
• 9.4 Covid Impact Historic and Forecast Sales by Regions
• 9.5 Pharmaceuticals & Biopharmaceuticals Historic and Forecast Sales by Regions
• 9.6 Cosmetic & Household Products Historic and Forecast Sales by Regions
• 9.7 Food Historic and Forecast Sales by Regions
• 9.8 Chemicals Historic and Forecast Sales by Regions

10 . GLOBAL IN VITRO TOXICITY TESTING MARKET ANALYSIS BY TECHNOLOGY

• 10.1 Overview by Technology
• 10.2 Historical and Forecast Data
• 10.3 Analysis by Technology
• 10.4 Cell Culture Technologies Historic and Forecast Sales by Regions
• 10.5 High-throughput Technologies Historic and Forecast Sales by Regions
• 10.6 Toxicogenomics Historic and Forecast Sales by Regions

11 . GLOBAL IN VITRO TOXICITY TESTING MARKET ANALYSIS BY GEOGRAPHY

• 11.1. Top Company Share Analysis
• 11.2. Introduction
• 11.3. North America Sales Analysis
  • 11.3.1. Overview, Historic and Forecast Sales Analysis
  • 11.3.2. North America By Segment Sales Analysis
  • 11.3.3. North America By Country Sales Analysis
  • 11.3.4. United State Sales Analysis
  • 11.3.5. Canada Sales Analysis
  • 11.3.6. Mexico Sales Analysis
• 11.4. Europe Sales Analysis
  • 11.4.1. Overview, Historic and Forecast Sales Analysis
  • 11.4.2. Europe by Segment Sales Analysis
  • 11.4.3. Europe by Country Sales Analysis
  • 11.4.4. United Kingdom Sales Analysis
  • 11.4.5. France Sales Analysis
  • 11.4.6. Germany Sales Analysis
  • 11.4.7. Italy Sales Analysis
  • 11.4.8. Russia Sales Analysis
  • 11.4.9. Rest Of Europe Sales Analysis
• 11.5. Asia Pacific Sales Analysis
  • 11.5.1. Overview, Historic and Forecast Sales Analysis
  • 11.5.2. Asia Pacific by Segment Sales Analysis
  • 11.5.3. Asia Pacific by Country Sales Analysis
  • 11.5.4. China Sales Analysis
  • 11.5.5. India Sales Analysis
  • 11.5.6. Japan Sales Analysis
  • 11.5.7. South Korea Sales Analysis
  • 11.5.8. Australia Sales Analysis
  • 11.5.9. Rest Of Asia Pacific Sales Analysis
• 11.6. Latin America Sales Analysis
  • 11.6.1. Overview, Historic and Forecast Sales Analysis
  • 11.6.2. Latin America by Segment Sales Analysis
  • 11.6.3. Latin America by Country Sales Analysis
  • 11.6.4. Brazil Sales Analysis
  • 11.6.5. Argentina Sales Analysis
  • 11.6.6. Peru Sales Analysis
  • 11.6.7. Chile Sales Analysis
  • 11.6.8. Rest of Latin America Sales Analysis
• 11.7. Middle East & Africa Sales Analysis
  • 11.7.1. Overview, Historic and Forecast Sales Analysis
  • 11.7.2. Middle East & Africa by Segment Sales Analysis
  • 11.7.3. Middle East & Africa by Country Sales Analysis
  • 11.7.4. Saudi Arabia Sales Analysis
  • 11.7.5. UAE Sales Analysis
  • 11.7.6. Israel Sales Analysis
  • 11.7.7. South Africa Sales Analysis
  • 11.7.8. Rest Of Middle East And Africa Sales Analysis

12 . COMPETITIVE LANDSCAPE OF THE IN VITRO TOXICITY TESTING COMPANIES

• 12.1. In Vitro Toxicity Testing Market Competition
• 12.2. Partnership/Collaboration/Agreement
• 12.3. Merger And Acquisitions
• 12.4. New Product Launch
• 12.5. Other Developments

13 . COMPANY PROFILES OF IN VITRO TOXICITY TESTING INDUSTRY

• 13.1. Company Share Analysis
• 13.2. Market Concentration Rate
• 13.3. Thermo Fisher Scientific Inc. (US)
  • 13.3.1. Company Overview
  • 13.3.2. Company Revenue
  • 13.3.3. Products
  • 13.3.4. Recent Developments
• 13.4. Covance (US)
  • 13.4.1. Company Overview
  • 13.4.2. Company Revenue
  • 13.4.3. Products
  • 13.4.4. Recent Developments
• 13.5. Bio-Rad Laboratories Inc. (US)
  • 13.5.1. Company Overview
  • 13.5.2. Company Revenue
  • 13.5.3. Products
  • 13.5.4. Recent Developments
• 13.6. GE Healthcare (US)
  • 13.6.1. Company Overview
  • 13.6.2. Company Revenue
  • 13.6.3. Products
  • 13.6.4. Recent Developments
• 13.7. Eurofins Scientific SE (Luxembourg)
  • 13.7.1. Company Overview
  • 13.7.2. Company Revenue
  • 13.7.3. Products
  • 13.7.4. Recent Developments
• 13.8. Merck KGaA (Germany)
  • 13.8.1. Company Overview
  • 13.8.2. Company Revenue
  • 13.8.3. Products
  • 13.8.4. Recent Developments
• 13.9. Charles River Laboratories International Inc. (US)
  • 13.9.1. Company Overview
  • 13.9.2. Company Revenue
  • 13.9.3. Products
  • 13.9.4. Recent Developments
• 13.10. Catalent Inc. (US)
  • 13.10.1. Company Overview
  • 13.10.2. Company Revenue
  • 13.10.3. Products
  • 13.10.4. Recent Developments
• 13.11. Cyprotex (UK)
  • 13.11.1. Company Overview
  • 13.11.2. Company Revenue
  • 13.11.3. Products
  • 13.11.4. Recent Developments
• 13.12. SGS S.A. (Switzerland)
  • 13.12.1. Company Overview
  • 13.12.2. Company Revenue
  • 13.12.3. Products
  • 13.12.4. Recent Developments
• 13.13. QIAGEN N.V. (Germany)
  • 13.13.1. Company Overview
  • 13.13.2. Company Revenue
  • 13.13.3. Products
  • 13.13.4. Recent Developments
• 13.14. Promega Corporation (US)
  • 13.14.1. Company Overview
  • 13.14.2. Company Revenue
  • 13.14.3. Products
  • 13.14.4. Recent Developments
• 13.15. Gentronix Limited (UK)
  • 13.15.1. Company Overview
  • 13.15.2. Company Revenue
  • 13.15.3. Products
  • 13.15.4. Recent Developments
• 13.16. BioIVT (US)
  • 13.16.1. Company Overview
  • 13.16.2. Company Revenue
  • 13.16.3. Products
  • 13.16.4. Recent Developments
• 13.17. MB Research Laboratories (US)
  • 13.17.1. Company Overview
  • 13.17.2. Company Revenue
  • 13.17.3. Products
  • 13.17.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies